Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Validating the Effect of Ondansetron and Mirtazapine in Treating Hyperemesis Gravidarum
NCT03785691Phase 2Terminated
- Sponsor
- Nordsjællands Hospital
- Start
- Mar 2019
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hyperemesis gravidarum (HG) comparing Mirtazapine, Ondansetron and Placebo (3 arms). Primary endpoint: Change in nausea and vomiting at 14 days. Started Mar 2019; status: terminated.
02
Drugs
mirtazapineondansetron
03
Conditions
hyperemesis gravidarum (HG)
Beyond the preview
Go deeper on NCT03785691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03785691.